Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034

被引：0
|
作者：
Ali, Haris [1 ]
Kishtagari, Ashwin [2 ]
Maher, Keri [3 ]
Mohan, Sanjay [2 ]
Prchal, Josef [4 ]
Wang, Xulong [5 ]
Chamoun, Kamal [5 ]
Tantravahi, Srinivas [4 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] VCU Massey Canc Ctr, Richmond, CA USA
[4] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[5] Karyopharm Therapeut, Newton, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
myelofibrosis; selinexor; ruxolitinib; phase I;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-336
引用
收藏
页码：S389 / S389
页数：1
相关论文
共 27 条
  • [21] BEYOND A BINARY ENDPOINT: LONGITUDINAL AND INDIVIDUAL SYMPTOM ANALYSES FROM THE SIMPLIFY-1 STUDY DEMONSTRATE CLINICALLY COMPARABLE SYMPTOMATIC BENEFIT OF MOMELOTINIB TO RUXOLITINIB IN JAK INHIBITOR NAIVE MYELOFIBROSIS PATIENTS
    Mesa, R.
    Hudgens, S.
    Floden, L.
    Palmer, J.
    Gupta, V
    McLornan, D. P.
    McMullin, M. F.
    Kiladjian, J. J.
    Foltz, L.
    Platzbecker, U.
    Fox, M. L.
    Mead, A. J.
    Ross, D. M.
    Oh, S. T.
    Perkins, A.
    Leahy, M. F.
    Deheshi, S.
    Donahue, R.
    Klencke, B. J.
    Verstovsek, S.
    VALUE IN HEALTH, 2021, 24 : S22 - S22
  • [22] BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
    Lavie, David
    Ribrag, Vincent
    Loschi, Michael
    Yannakou, Costas K.
    Alwan, Maan
    Abulafia, Adi Schacham
    Hernandez-Rivas, Jesus Maria
    Volchek, Yulia
    Fong, Chun Yew
    Bonifacio, Massimiliano
    Kiladjian, Jean-Jacques
    Ianotto, Jean-Christophe
    Garcia Gutierrez, Valentin
    Tucci, Alessandra
    Xicoy, Blanca
    Al-Ali, Haifa Kathrin
    Talpaz, Moshe
    Gerber, Jonathan M.
    Raman, Indu
    Tomuleasa, Ciprian
    Lee-Hoeflich, Si Tuen
    Das, Sharmila
    Wu, Bin
    Zhao, Qian
    Kim, Eunhee
    Esposito, Oriana
    Liu, Yu
    Nikolova, Zariana
    Tehlirian, Christopher
    Coker, Shodeinde
    Ayala, Rosa
    BLOOD, 2023, 142
  • [23] Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis
    Rampal, Raajit
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron Thomas
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Kuykendall, Andrew Tucker
    Mesa, Ruben A.
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Harris, Morgan
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    Mascarenhas, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)
    Talpaz, M.
    Jamieson, C.
    Gabrail, N.
    Lebedinsky, C.
    Gao, G.
    Patki, A.
    Lui, F.
    Tefferi, A.
    Pardanani, A.
    HAEMATOLOGICA, 2013, 98 : 458 - 458
  • [25] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
    Pardanani, Animesh
    Tefferi, Ayalew
    Masszi, Tamas
    Mishchenko, Elena
    Drummond, Mark W.
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Jurgutis, Mindaugas
    Ribrag, Vincent
    Rambaldi, Alessandro
    Koh, Liang Piu
    Rose, Shelonitda
    Zhang, Jun
    Harrison, Claire
    BLOOD, 2020, 136
  • [26] Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
    Gupta, Vikas
    Yacoub, Abdulraheem
    Verstovsek, Srdan
    Mesa, Ruben A.
    Harrison, Claire N.
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Deeg, H. Joachim
    Fazal, Salman
    Foltz, Lynda
    Mattison, Ryan J.
    Miller, Carole B.
    Parameswaran, Vinod
    Gharpure, Vishwanath
    Hernandez, Christopher
    Wang, Tianhua
    Talpaz, Moshe
    BLOOD, 2021, 138
  • [27] Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naive Patients with ALK plus Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
    Cho, Byoung Chul
    Kim, Dong-Wan
    Batra, Ullas
    Park, Keunchil
    Kim, Sang -We
    Yang, Cheng-Ta
    Voon, Pei-Jye
    Sriuranpong, Virote
    Babu, K. Govind
    Amin, Khalid
    Wang, Yingbo
    Sen, Paramita
    Slimane, Khemaies
    Geater, Sarayut
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 83 - 93
123